Pipeline & Products
Arovella is developing its iNKT cell therapy platform to treat blood cancers, solid tumours and autoimmune disease.
ALA-101 CD19-targeting CAR-iNKT cells
ALA-101 is a next-generation "off-the-shelf" CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias. Arovella’s SAPPHIRE phase 1 trial is designed to generate the B cell depletion, safety, persistence and durability data that may support the evaluation of ALA-101 in autoimmune disease.
ALA-105 CLDN18.2-targeting CAR-iNKT cells
Arovella has entered into a global, exclusive license with Sparx Group to develop a world-first iNKT cell therapy targeting Claudin 18.2 (CLDN18.2), which is expressed in gastric cancer (GC), gastroesophageal junction cancer (GEJC) and pancreatic cancer (PC).